Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.39 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.37 |
| ▸ | TNKS | O95271 | 1/20 | 0.36 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.36 |
| ▸ | QPCT | Q16769 | 1/20 | 0.33 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 2/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | LCK | P06239 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22792404 | 0.78 | IDO1 (0.42) | IDO1TBXAS1TNKSTNKS2QPCT | |
| SCHEMBL23065942 | 0.73 | TBXAS1 (0.57) | IDO1TBXAS1TNKSTNKS2QPCT | |
| SCHEMBL13271311 | 0.69 | TBXAS1 (0.47) | IDO1TBXAS1QPCTQPCTLTDO2 | |
| SCHEMBL22793032 | 0.68 | IDO1 (0.42) | IDO1TBXAS1TNKSTNKS2QPCT | |
| SCHEMBL24656778 | 0.67 | KDM5A (0.36) | IDO1TBXAS1 | |
| SCHEMBL12698776 | 0.67 | QPCT (0.51) | IDO1TBXAS1QPCTQPCTLTDO2 | |
| SCHEMBL22792984 | 0.66 | TNKS (0.33) | TNKSTNKS2 | |
| SCHEMBL20689814 | 0.66 | QPCT (0.46) | IDO1TBXAS1TNKSTNKS2QPCT | |
| SCHEMBL24656099 | 0.66 | TBXAS1 (0.50) | IDO1TBXAS1TNKSTNKS2QPCT | |
| SCHEMBL21718777 | 0.65 | QPCT (0.42) | IDO1TBXAS1TNKSTNKS2QPCT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200392128-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392128-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | PTPN5, PTPN1, PTPRJ | IDO1 1490/4885TBXAS1 1358/4885TNKS 2087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.